MBN 101

Drug Profile

MBN 101

Alternative Names: BisEDT Antimicrobial Gel; MBN-101; MBS-101

Latest Information Update: 23 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Microbion Corporation
  • Class Anti-infectives; Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bacterial infections
  • Phase I/II Diabetic foot ulcer

Most Recent Events

  • 03 Mar 2017 Phase-I/II clinical trials in Diabetic foot ulcer (Adjunctive treatment) in USA (Topical) (NCT02723539)
  • 04 Aug 2016 MBN 101 receives fast track status for Diabetic foot ulcer in USA
  • 26 May 2016 MBN 101 receives Qualified Infectious Disease Product status for Diabetic foot ulcer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top